LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Akcijų sąrašas・Gilead Sciences Inc.

Gilead Sciences Inc.

Uždarymo kaina

SektoriusSveikatos priežiūra

129.14 0.07

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

127.96

Max

130.87

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-162M 2B
Pardavimai	-965M 7B
P/E Sektoriaus vid.	17.837 49.888
Pelnas, tenkantis vienai akcijai	2.03
Dividendų pajamingumas	2.37
Pelno marža	29.037
Darbuotojai	17,000
EBITDA	1.2B 3.5B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+24.13% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.37% 2.38%
Kitas uždarbis	2026-08-06
Kitas dividendų mokėjimo data	2026-06-29
Kita Ex Dividend data	2026-06-15

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.9B 163B
Ankstesnė atidarymo kaina	129.07
Ankstesnė uždarymo kaina	129.14

Naujienos nuotaikos

By Acuity

12%

88%

15 / 344 reitingas Healthcare

Gilead Sciences Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-07 20:49; UTC

Uždarbis

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

2026-04-07 14:24; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update

2026-04-07 12:53; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

2026-06-04 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026-05-08 08:10; UTC

Uždarbis

Gilead Stock Falls After Earnings. A Big Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-08 08:08; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-07 22:33; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026-05-07 21:09; UTC

Uždarbis

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

2026-05-07 20:51; UTC

Uždarbis

Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut? -- Barrons.com

2026-05-07 20:06; UTC

Uždarbis

Gilead Sciences Raises 2026 View To Sales $30B-$30.4B >GILD

2026-05-07 20:05; UTC

Uždarbis

Gilead Sciences Sees 2026 Adj Loss/Shr 65c-Adj Loss/Shr $1.05 >GILD

2026-05-07 20:05; UTC

Uždarbis

Gilead Sciences Sees 2026 Loss/Shr $2.85-Loss $3.25 >GILD

2026-05-07 20:02; UTC

Uždarbis

Gilead Sciences: Biktarvy Sales Increased 7% Yr-Over-Yr to $3.4B >GILD

2026-05-07 20:01; UTC

Uždarbis

Gilead Sciences 1Q Rev $6.96B >GILD

2026-05-07 20:01; UTC

Uždarbis

Gilead Sciences 1Q Adj EPS $2.03 >GILD

2026-05-07 20:01; UTC

Uždarbis

Gilead Sciences 1Q Total Liver Disease Sales $767M >GILD

2026-05-07 20:01; UTC

Uždarbis

Gilead Sciences 1Q EPS $1.61 >GILD

2026-04-28 12:45; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences Completes Acquisition Of Arcellx Ahead Of Potential Commercial Launch Of Anito-cel >GILD

2026-04-17 12:32; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences Extends Arcellx Tender Offer >GILD ACLX

2026-04-17 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Receives All Required Regulatory Approvals For The Acquisition Of Arcellx And Extends Tender Offer >GILD

2026-04-07 14:36; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences: The Deal Is Expected to Close in 2Q of 2026

2026-04-07 14:35; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences: Gilead Plans to Finance Transaction With Cash and Senior Unsecured Notes

2026-04-07 14:34; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences: Gilead Will Also Buy TUB-030

2026-04-07 14:28; UTC

Įsigijimai, susijungimai, perėmimai

EQT Life Sciences to Exit Minority Stake in Tubulis via Sale to Gilead Sciences for Up to $5B

2026-04-07 14:23; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Gilead Buying Another Cancer-Drug Partner -- Market Talk

2026-04-07 13:55; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Gilead Continues Buying Spree with Tubulis Deal -- Market Talk

2026-04-07 13:14; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion -- Barrons.com

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences to Finance Tubulis Deal With Cash on Hand, Senior Unsecured Notes >GILD

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Tubulis Deal Antibody-Drug Conjugates on Oncology Pipeline >GILD

2026-04-07 12:30; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences: Tubulis Deal Includes Up to $1.85 Billion Contingent Milestone Payments >GILD

Akcijų palyginimas

Kainos pokytis

Gilead Sciences Inc. Prognozė

Kainos tikslas

By TipRanks

24.13% į viršų

12 mėnesių prognozė

Vidutinis 160.11 USD 24.13%

Aukščiausias 180 USD

Žemiausias 122 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Gilead Sciences Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

Pirkti

Laikyti

Parduoti

Remiantis 21 analitikų, pateikusių Gilead Sciences Inc. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

15 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.